CN111676011B - 一种吲哚菁绿-磷脂复合物及其制备方法和应用 - Google Patents
一种吲哚菁绿-磷脂复合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111676011B CN111676011B CN202010387159.9A CN202010387159A CN111676011B CN 111676011 B CN111676011 B CN 111676011B CN 202010387159 A CN202010387159 A CN 202010387159A CN 111676011 B CN111676011 B CN 111676011B
- Authority
- CN
- China
- Prior art keywords
- icg
- phospholipid
- iron
- imaging
- phospholipid complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 238000010668 complexation reaction Methods 0.000 title description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 96
- 229910052742 iron Inorganic materials 0.000 claims abstract description 54
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 19
- -1 iron ions Chemical class 0.000 claims abstract description 14
- 238000005481 NMR spectroscopy Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000003384 imaging method Methods 0.000 claims description 33
- 206010065973 Iron Overload Diseases 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 4
- 230000029142 excretion Effects 0.000 claims description 4
- 229910001447 ferric ion Inorganic materials 0.000 claims description 4
- 229940083466 soybean lecithin Drugs 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000005284 excitation Effects 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 7
- 208000031306 Rare hereditary hemochromatosis Diseases 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000009920 chelation Effects 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000005294 ferromagnetic effect Effects 0.000 abstract description 2
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 abstract 2
- 229960000958 deferoxamine Drugs 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 239000013522 chelant Substances 0.000 abstract 1
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003595 spectral effect Effects 0.000 abstract 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 27
- 229960004657 indocyanine green Drugs 0.000 description 27
- 238000001514 detection method Methods 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 10
- 238000002595 magnetic resonance imaging Methods 0.000 description 10
- 230000008021 deposition Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 5
- 102000008857 Ferritin Human genes 0.000 description 4
- 108050000784 Ferritin Proteins 0.000 description 4
- 238000008416 Ferritin Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6402—Atomic fluorescence; Laser induced fluorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- High Energy & Nuclear Physics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Optics & Photonics (AREA)
- Acoustics & Sound (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明公开了一种吲哚菁绿‑磷脂复合物及其制备方法和应用。本发明中制备的两亲性ICG‑磷脂复合物在体外和体内同时展现出良好的鳌合铁离子的能力。通过该螯合作用，铁磁学性质和ICG自身光谱性质会受到影响，并且可通过检测核磁共振信号变化值、荧光信号以及光声信号变化值定量体内外活性铁量，从而用于诊断铁过载疾病程度。本发明还涉及所述ICG/磷脂复合物可显著降低活体动物铁负荷，展示出优于临床用去铁敏(DFO)的去铁疗效。本发明中使用的ICG和磷脂为临床应用药物，构建的复合物具有很强的临床应用可行性，从而使得该两亲性ICG‑磷脂复合物为铁过载疾病的临床诊疗提供了新的方案。
Description
技术领域
本发明涉及吲哚菁绿-磷脂复合物及其制备方法和应用。
背景技术
铁过载是指铁代谢异常，体内铁含量超过正常水平所导致的一种病理状态。当体内铁含量超过转铁蛋白的结合能力时，铁便会在体内某些部位沉积，通过Fenton反应产生大量氧化自由基，引起脂质、蛋白质、核酸损伤，从而导致肝脏、心脏、胰腺、垂体、关节等重要部位的结构损害和功能障碍，与肝癌、贫血、骨质疏松、子宫内膜异位等多种疾病有关，其中肝脏是最主要的肝代谢和储存器官，故体内铁沉积情况对肝脏健康状态有非常大的影响，并且与肝细胞癌(HCC)关系尤为密切。遗传因素和输血过量都可能引起铁过载的发生，当患者接受了20个单位以上的红细胞输注或血清铁蛋白大于1000ug/L，就可诊断为铁过载。鉴于铁过载患者症状多样、病情发展缓慢、早期不易被发现，但肝脏中的过量铁沉积会加重某些肝病原有的损伤、促使其发生纤维化甚至肝硬化的事实，准确定量检测、尽早发现并降低铁过载对防止铁代谢紊乱发展成肝癌至关重要。
目前，测量铁过载的方法主要有肝组织活检、血清铁蛋白(serum ferritin，SF)检测、SQUID检测、CT检查、磁共振成像(magnetic resonance imaging，MRI)等，其中MRI因其高准确性、良好的可重复性以及无创的特点而备受青睐。MRI是检测铁过载程度的一种新兴的方法。它利用肝脏中铁沉积会引起肝内水质子扩散的磁性不均匀的现象对肝脏中的信号改变进行监测，从而来间接测量肝铁浓度，敏感性较为出色。目前国内外用于检测铁过载的MRI方法主要有：信号强度测量法(包括信号强度比(signal intensity ratio，SIR)和同反相位信号强度差异)、T2/R2测量法(如多回波mapping技术和Ferri Scan技术)、T2/R2测量法、Dixon及其衍生技术、超短回波时间(ultroshort echo time，UTE)成像技术及磁敏感加权成像技术(包括常规磁敏感加权成像和定量磁敏感图(quantitative susceptibilitymapping，QSM))。但是在使用MRI进行铁过载测量时，损伤肝脏中的脂肪量和由大量铁过载引起的异常信号会提供不准确的铁浓度评估，因此,改进当前MRI检测方法或引入其他成像方法来精确、无创地检测体内过量的铁具有临床必然性。
发明内容
针对现有铁过载疾病诊疗技术的不足，本发明的主要目的在于提供一种基于ICG(吲哚菁绿)-磷脂复合物的制备方法及其应用。
本发明利用一种基于ICG的自组装复合体系作为造影剂和光敏剂，将MRI与PAI(光声成像)结合起来，构建一种多模态铁过载检测方法，能够实现对肝脏中铁浓度的精确、无创、动态测量。
本发明提供的ICG及ICG-磷脂复合物具有良好的生物相容性和荧光性质、优异的铁螯合性能。该ICG-磷脂与铁形成络合物造成的荧光性质和铁磁性质变化提供了荧光和核磁检测信号。本发明所述ICG-磷脂与铁形成络合物提供890nm波长处光学性质的变化，便于实现进一步光声成像性能，为铁过载诊疗附加更多的功能。且ICG-磷脂体现出增加体内铁排泄和降低活体血清铁蛋白水平的功能。
与现有技术相比，本发明取得的突出技术效果包括：
(1)利用Fe3+与ICG-磷脂复合物结合过程中，Fe3+浓度与T1值负相关的特性，实现使用多种核磁共振成像方法对铁沉积浓度的精确定量检测与动态监测。
(2)利用Fe3+与ICG-磷脂复合物结合过程中，Fe3+浓度与荧光信号值相关的特性，实现使用荧光成像仪对铁沉积浓度的精确定量检测与动态监测。
(3)利用Fe3+与ICG-磷脂复合物结合过程中，Fe3+浓度与890nm激发光下光声信号值相关的特性，实现使用光声成像仪对铁沉积浓度的精确定量检测与动态监测。
(4)提供一种新的针对铁过载的多模态成像检测方法，将由磁共振成像(MRI)提供的高空间分辨率和由在890nm处吸光增强的光声成像(PAI)信号提供的丰富的光学对比度结合起来,从而更好地提供治疗计划和评估治疗结果。
(3)利用ICG-磷脂可以显著促进体内铁排泄和降低活体内血清铁蛋白水平的特性，实现对铁过载的诊疗一体化。
附图说明
图1单纯铁离子、磷脂+铁离子、吲哚菁绿+磷脂+铁离子、吲哚菁绿+铁离子在1.5T核磁共振仪中的1/T1信号值。
图2吲哚菁绿-磷脂中加入不同浓度铁离子对应的光声信号值。附图为光声信号图。
图3 100μM铁离子中加入吲哚菁绿和吲哚菁绿+磷脂，离心取上清铁浓度测定。
具体实施方式
以下通过具体的制备例和实施例可使本发明得到更清楚的说明，但本发明的整体构思并不局限于该实施例，本领域的专业技术人员往往可以通过同样的思路对实验中的某一步进行替换，但本发明的整体思路仍受保护：
本发明所述的一种ICG-磷脂复合物，包括ICG、磷脂以及作为溶剂的水，其中，所述的ICG：磷脂摩尔比例为1:10-10:1，磷脂和ICG在水中的浓度分别为0.05-5mg/mL。
在本发明中，所述的磷脂是含有磷酸的脂类中的任意一种。作为优选，所述的磷脂为大豆卵磷脂。
本发明一种ICG-磷脂复合物的制备方法，包括以下步骤：
磷脂和ICG分别分散为水溶液，并且浓度分别为0.1-10mg/mL；将两种溶液进行混合。
本发明靶标中活性铁离子浓度的检测方法，包括如下步骤：
(1)制备前述的ICG-磷脂复合物；
(2)对成像目标注射所述ICG-磷脂复合溶液，利用核磁共振成像仪中的包括T1,T1*,T2,T2*,GRE,QSM在内的序列扫描所述成像目标的待扫描区域，成像出具有铁范围的结构图像并获得信号值，及计算出信号变化值对应总铁浓度；或
对成像和治疗目标注射所述ICG-磷脂复合溶液，利用光声成像仪中890nm处波长的光源激发扫描所述成像目标的待扫描区域并且成像出具有铁范围的结构图像并获得信号变化值，及计算出信号值对应总铁浓度；或
对成像和治疗目标注射所述ICG-磷脂复合溶液，利用荧光成像仪光源激发扫描所述成像目标的待扫描区域并且成像出具有铁范围的结构图像。
在本发明的优选实施例中，所述成像目标为含铁活性铁离子的物质，包括液体、病理切片、生物组织中的至少一种。
在本发明的优选实施例中，所述荧光信号值为激发波长在230-1000nm。
两亲性ICG(吲哚菁绿)是一种已经被FDA批准用于临床的药物，已被用来作为动态评估肝功能和病人心输出量的标准。
实施例1
(a)吲哚菁绿溶液：首先，称取1mg吲哚菁绿小分子，加入1mL去离子水溶液并利用超声波清洗器超声2min使其完全溶解；
(b)吲哚菁绿-磷脂复合物：分别称取1mg吲哚菁绿小分子和大豆卵磷脂，分别加入1mL去离子水溶液并利用超声波清洗器超声2min使其完全溶解；而后1:1混合均匀备用；
实施例2
结合附图，在一些实施方式中，下述的成像目标为含铁水溶液。
(1)在100μL不同浓度(0-500μM)的高铁水溶液中加入100μL所述ICG(500μM)-磷脂(1mM)复合溶液，混合均匀，利用核磁共振成像仪扫描所述成像目标的待扫描区域和计算出信号值。如图1所示，可以看出本发明中制备的ICG-磷脂复合溶液890nm处光声值随铁离子浓度升高而升高，补充增强了MRI成像灵敏度不足的问题。
(2)在100μL不同浓度(0-500μM)的高铁水溶液中加入100μL ICG(500μM)、磷脂(1mM)、ICG(500μM)-磷脂(1mM)复合溶液，混合均匀，利用核磁共振成像仪扫描所述成像目标的待扫描区域并及计算出信号值。如图2所示，可以看出本发明中制备的ICG(500μM)、ICG-磷脂复合溶液可完全屏蔽铁离子浓度的T1信号值，这为用MRI定量活性铁离子浓度提供新的思路。在实际操作中，T2信号值也具备相应的信号变化趋势。
(3)在1mL 500μM的高铁水溶液中加入1mL所述ICG(500μM)、ICG(500μM)-磷脂(1mM)复合溶液,后5000转/分钟离心5分钟取上清。如图3所示，ICG、ICG-磷脂与活性铁离子结合后皆可增大结构密度，从而达到离心去除铁的作用，这将有利于促进体内过载铁的排泄。结合上述成像方式，利于实现对铁过载程度的动态监测和诊疗一体化。
Claims (7)
1.一种ICG-磷脂复合物，所述的复合物包括ICG、磷脂以及作为溶剂的水，其中，所述的ICG：磷脂摩尔比例为1:10-10:1，磷脂和ICG在水中的浓度分别为0.05-5mg/mL；所述的磷脂为大豆卵磷脂。
2.如权利要求1所述的一种ICG-磷脂复合物的制备方法，包括以下步骤：
磷脂和ICG分别分散为水溶液，并且浓度分别为0.1-10mg/mL；将两种溶液进行混合。
3.如权利要求1所述的ICG-磷脂复合物在制备铁过载诊断试剂中的应用。
4.如权利要求1所述的ICG-磷脂复合物在制备铁过载的铁排泄药物中的应用。
5.靶标中活性铁离子浓度的检测方法，用于非疾病诊断和治疗目的，包括如下步骤：
(1)制备权利要求1或2所述的ICG-磷脂复合物；
(2)对成像目标注射所述ICG-磷脂复合溶液，利用核磁共振成像仪中的包括T1,T1*,T2,T2*,GRE,QSM在内的序列扫描所述成像目标的待扫描区域，成像出具有铁范围的结构图像并获得信号值，及计算出信号变化值对应总铁浓度；或
对成像和治疗目标注射所述ICG-磷脂复合溶液，利用光声成像仪中890nm处波长的光源激发扫描所述成像目标的待扫描区域并且成像出具有铁范围的结构图像并获得信号变化值，及计算出信号值对应总铁浓度；或
对成像和治疗目标注射所述ICG-磷脂复合溶液，利用荧光成像仪光源激发扫描所述成像目标的待扫描区域并且成像出具有铁范围的结构图像。
6.如权利要求5所述的方法，其特征在于，所述成像目标为含铁活性铁离子的物质，包括液体、病理切片、生物组织中的至少一种。
7.如权利要求5所述的方法，其特征在于，所述荧光信号值为激发波长在230-1000nm。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387159.9A CN111676011B (zh) | 2020-05-09 | 2020-05-09 | 一种吲哚菁绿-磷脂复合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010387159.9A CN111676011B (zh) | 2020-05-09 | 2020-05-09 | 一种吲哚菁绿-磷脂复合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111676011A CN111676011A (zh) | 2020-09-18 |
| CN111676011B true CN111676011B (zh) | 2021-10-26 |
Family
ID=72452445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010387159.9A Active CN111676011B (zh) | 2020-05-09 | 2020-05-09 | 一种吲哚菁绿-磷脂复合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111676011B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103690486A (zh) * | 2013-12-27 | 2014-04-02 | 深圳先进技术研究院 | 一种吲哚菁绿纳米靶向脂质体及其制备方法和应用 |
| CN105530920A (zh) * | 2013-09-12 | 2016-04-27 | 智能输送有限公司 | 通过纳米结构的载体系统引起的细胞特异性靶向作用 |
| CN107349433A (zh) * | 2017-06-30 | 2017-11-17 | 中国科学院自动化研究所 | 近红外纳米探针、制备方法及全息分子影像导航系统 |
| CN108578696A (zh) * | 2018-05-15 | 2018-09-28 | 厦门大学 | 一种脂质体微泡载金属-icg自组装复合体系 |
| CN110960694A (zh) * | 2019-12-12 | 2020-04-07 | 深圳先进技术研究院 | 一种用于近红外二区荧光检测的吲哚菁绿脂质体及其制备方法和用途 |
-
2020
- 2020-05-09 CN CN202010387159.9A patent/CN111676011B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105530920A (zh) * | 2013-09-12 | 2016-04-27 | 智能输送有限公司 | 通过纳米结构的载体系统引起的细胞特异性靶向作用 |
| CN103690486A (zh) * | 2013-12-27 | 2014-04-02 | 深圳先进技术研究院 | 一种吲哚菁绿纳米靶向脂质体及其制备方法和应用 |
| CN107349433A (zh) * | 2017-06-30 | 2017-11-17 | 中国科学院自动化研究所 | 近红外纳米探针、制备方法及全息分子影像导航系统 |
| CN108578696A (zh) * | 2018-05-15 | 2018-09-28 | 厦门大学 | 一种脂质体微泡载金属-icg自组装复合体系 |
| CN110960694A (zh) * | 2019-12-12 | 2020-04-07 | 深圳先进技术研究院 | 一种用于近红外二区荧光检测的吲哚菁绿脂质体及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111676011A (zh) | 2020-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | Development of methods and feasibility of using hyperpolarized carbon‐13 imaging data for evaluating brain metabolism in patient studies | |
| Chen et al. | Assessing prostate cancer aggressiveness with hyperpolarized dual-agent 3D dynamic imaging of metabolism and perfusion | |
| Zhang et al. | A new NOE-mediated MT signal at around− 1.6 ppm for detecting ischemic stroke in rat brain | |
| Wen et al. | MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast | |
| Yen et al. | T2 relaxation times of 13C metabolites in a rat hepatocellular carcinoma model measured in vivo using 13C‐MRS of hyperpolarized [1‐13C] pyruvate | |
| Zhou et al. | MRI of stroke using hyperpolarized 129Xe | |
| Wang et al. | Albumin-based nanoparticles loaded with hydrophobic gadolinium chelates as T 1–T 2 dual-mode contrast agents for accurate liver tumor imaging | |
| Hyodo et al. | Monitoring redox-sensitive paramagnetic contrast agent by EPRI, OMRI and MRI | |
| Straathof et al. | Deuterium metabolic imaging of the healthy and diseased brain | |
| Hu et al. | Assessing intrarenal nonperfusion and vascular leakage in acute kidney injury with multinuclear 1H/19F MRI and perfluorocarbon nanoparticles | |
| US20130096415A1 (en) | Method to determine sodium values describing the content of 23na+, and local coil for use in such a method | |
| Yang et al. | Oxygen‐sensitive MRI assessment of tumor response to hypoxic gas breathing challenge | |
| Antonelli et al. | Ferucarbotran-loaded red blood cells as long circulating MRI contrast agents: first in vivo results in mice | |
| Huang et al. | Novel gradient echo sequence‑based amide proton transfer magnetic resonance imaging in hyperacute cerebral infarction | |
| Bolcaen et al. | In vivo DCE-MRI for the discrimination between glioblastoma and radiation necrosis in rats | |
| Niles et al. | Evaluation of renal metabolic response to partial ureteral obstruction with hyperpolarized 13C MRI | |
| Ianniello et al. | Multinuclear MRI to disentangle intracellular sodium concentration and extracellular volume fraction in breast cancer | |
| Perman et al. | Multiple short‐echo (2.5‐ms) quantitation of in vivo sodium T2 relaxation | |
| Edlund et al. | Reduced oxygenation in diabetic rat kidneys measured by T2* weighted magnetic resonance micro-imaging | |
| Tyagi et al. | Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: Applications in interstitial cystitis and beyond | |
| Jung et al. | Longitudinal Magnetic Resonance Imaging with ROS‐Responsive Bilirubin Nanoparticles Enables Monitoring of Nonalcoholic Steatohepatitis Progression to Cirrhosis | |
| Kirschner et al. | Differentiation of acute and four-week old myocardial infarct with Gd (ABE-DTTA)-enhanced CMR | |
| CN111676011B (zh) | 一种吲哚菁绿-磷脂复合物及其制备方法和应用 | |
| Song et al. | Quantitative T2* imaging of metastatic human breast cancer to brain in the nude rat at 3 T | |
| Kim et al. | Sensitive detection of extremely small iron oxide nanoparticles in living mice using MP2RAGE with advanced image co-registration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |